What was studied — not what to take
Ipamorelin Dosage as It Appears in the Research
The doses, routes, and pharmacokinetics that studies actually used — reported in the third person, as research context, never as a human protocol.
Read this first
This page describes ipamorelin dosage the way the studies report it — which species got how much, by which route, for how long — and nothing more. It is not a protocol, a recommendation, or a how-to. There is no established human dose for ipamorelin, because it was never approved and its single human efficacy trial used a hospital-administered intravenous regimen that did not work [3]. Where community combination protocols come up, they are flagged as anecdotal and unvalidated, with no peer-reviewed human dosing basis. The useful, real numbers here are the pharmacokinetics — how long ipamorelin lasts and how fast the GH pulse peaks — because those were measured in people [2]. Everything framed as "take this much" anywhere online is extrapolation, not evidence.
Doses and routes used in studies
Across the published record, ipamorelin has been administered in tightly controlled experimental settings:
- Human pharmacokinetics: single intravenous infusions of 4.21 to 140.45 nmol/kg over 15 minutes in healthy male volunteers [2].
- Human Phase 2 trial: 0.03 mg/kg intravenously twice daily for up to 7 days in bowel-resection patients [3].
- Rat bone growth: 18, 90, and 450 µg/day subcutaneously, divided three times daily, for 15 days [4].
- Ferret cachexia (2024): 1–3 mg/kg intraperitoneally [5].
The routes studied span intravenous (human trials and rodent efficacy), subcutaneous (the rodent bone and body-composition work, and the dominant route in community use), intraperitoneal (rodent and ferret studies), and intranasal (rodent pharmacokinetics, around 20% bioavailability). Ipamorelin itself is not orally active — only engineered analogs achieve oral absorption [7]. Note the gap: the route most people actually use, subcutaneous self-injection, has no published human dosing or safety characterization at all.
Half-life and how fast the GH pulse arrives
This is the part of ipamorelin dosage that rests on real human data. In healthy volunteers, ipamorelin showed a terminal half-life of approximately 2 hours, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The pharmacokinetics were linear and dose-proportional. The growth-hormone response it triggers is a single discrete pulse that peaks about 40 minutes (0.67 h) after dosing [2]. In rats, plasma clearance runs roughly five-fold lower than the older peptide GHRP-6. The short half-life and quick, single GH pulse are why the compound is studied as a pulsatile stimulus rather than a steady one.
How much cjc-1295 ipamorelin should i take
There is no evidence-based answer to how much cjc-1295 ipamorelin someone should take, and this site will not invent one. No controlled human trial has tested the CJC-1295 + ipamorelin combination for any outcome, so there is no validated dose, ratio, or schedule for it. The community subcutaneous protocols circulating online are not supported by peer-reviewed human dosing data and are described here only as anecdotal practice, not as guidance. The single controlled human ipamorelin regimen on record (0.03 mg/kg IV twice daily) was a hospital-administered trial dose that failed its endpoint [3] — not a template for self-use. Any specific milligram figure attached to a "stack" is extrapolation from animal pharmacology, not a finding.
How to reconstitute cjc-1295 ipamorelin 5mg
On the question of how to reconstitute cjc-1295 ipamorelin 5mg, the only thing the research-supply literature actually documents is general peptide-handling: ipamorelin is supplied as a lyophilized (freeze-dried) powder, as either the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is typically kept refrigerated. These are general handling observations from the supply literature, not a clinical preparation instruction and not a step-by-step protocol for human use. No validated human reconstitution or dosing procedure exists for ipamorelin, alone or combined with CJC-1295.
Stability and handling notes
Ipamorelin's physical handling is straightforward in research terms and unremarkable for a peptide. It ships lyophilized and is reconstituted before use; the solution is heat- and freeze-thaw-sensitive and kept cold. A separate, non-handling caution belongs here too: research-grade ipamorelin from unregulated suppliers is not subject to pharmaceutical quality control, so identity, purity, and sterility are unverified [3]. The handling literature tells you how the powder behaves; it tells you nothing about whether a given gray-market vial contains what its label claims.